参考文献/References:
[1].enjamin EJ,Blaha MJ,Chiuve SE,et al. Heart Disease and Stroke Statistics-2017 Update:A Report From the American Heart Association[J]. Circulation,2017,135(10):e146-e603.
[2].胡大一. 降低密度脂蛋白胆固醇是硬道理[J]. 中华心血管病杂志,2015,43(1):3-4.
[3].Catapano AL,Graham I,De Backer G,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias[J]. Rev Esp Cardiol (Engl Ed),2017,70(2):115.
[4].Grundy SM,Stone NJ,Bailey AL,et al. 2018AHA/ACC/AACVPR /AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation,2019,139(25): e1082-e1143.
[5].Chasman DI,Giulianini F,MacFadyen J,et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction:the Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial[J]. Circ Cardiovasc Genet,2012,5(2):257-264.
[6].Thompson JF,Hyde CL,Wood LS,et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort[J]. Circ Cardiovasc Genet, 2009,2(2):173-181.
[7].Gitt AK,Lautsch D,Ferrieres J,et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin- treated patients[J]. Atherosclerosis,2016,255:200-209.
[8].Dyrbu? K,Osadnik T,Desperak P,et al. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry[J]. Pharmacol Res,2018,132:204-210.
[9].Hobbs FD,Banach M,Mikhailidis DP,et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease?A pro/con debate[J]. BMC Med,2016,14:4.
[10].Newman CB,Preiss D,Tobert JA,et al. American Heart Association Clinical Lipidology,Lipoprotein,Metabolism and Thrombosis Committee,a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health;Council on Cardiovascular Disease in the Young;Council on Clinical Cardiology and Stroke Council. Statin Safety and Associated Adverse Events:A Scientific Statement From the American Heart Association[J]. Arterioscler Thromb Vasc Biol,2019,39(2):e38-e81.
[11].Urban D,P?ss J,B?hm M,et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis[J]. J Am Coll Cardiol,2013,62 (16):1401-1408.
[12].Gu HM,Adijiang A,Mah M,et al. Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding[J]. J Lipid Res,2013,54(12):3345-3357.
[13].Lagace TA,Curtis DE,Garuti R,et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11):2995-3005.
[14].Seidah NG,Prat A. The biology and therapeutic targeting of the proprotein convertases[J]. Nat Rev Drug Discov,2012,11(5):367-383.
[15].Bergeron N,Phan BA,Ding Y,et al. Proprotein convertase subtilisin/kexin type 9 inhibition:a new therapeutic mechanism for reducing cardiovascular disease risk[J]. Circulation,2015,132(17):1648-1666.
[16].Dragan S,Serban MC,Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors:an emerging lipid-lowering therapy?[J]. J Cardiovasc Pharmacol Ther,2015,20(2):157-168.
[17].Banach M,Rizzo M,Nikolic D,et al. Intensive LDL-cholesterol lowering therapy and neurocognitive function[J]. Pharmacol Ther,2017,170:181-191.
[18].Ridker PM,Tardif JC,Amarenco P,et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab[J]. N Engl J Med,2017,376(16):1517-1526.
[19].Fitzgerald K,White S,Borodovsky A,et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med,2017,376(1):41-51.
[20].Frank-Kamenetsky M,Grefhorst A,Anderson NN,et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates[J]. Proc Natl Acad Sci U S A,2008,105(33):11915-11920.
[21].Fitzgerald K,Frank-Kamenetsky M,Shulga-Morskaya S,et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers:a randomised,single-blind,placebo-controlled,phase 1 trial[J]. Lancet,2014,383(9911),383:60-68.
[22].Khvorova A. Oligonucleotide Therapeutics-A New Class of Cholesterol-Lowering Drugs[J]. N Engl J Med,2017,376(1):4-7.
[23].Vena GA,Cassano N,Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis[J]. Ther Clin Risk Manag,2018,14:105-116.
[24].Ray KK,Landmesser U,Leiter LA,et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med,2017,376(15):1430-1440.
[25].Chi X,Gatti P,Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics[J]. Drug Discov Today,2017,22(5):823-833.
[26].Flierl U,Nero TL,Lim B,et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators[J]. J Exp Med,2015,212(2):129-137.
[27].Schmidt AF,Swerdlow DI,Holmes MV,et al. PCSK9 genetic variants and risk of type 2 diabetes:a mendelian randomisation study[J]. Lancet Diabetes Endocrinol,2017,5(2):97-105.
[28].Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins:prespecified secondary end points in ORION 1[J]. Circulation,2018,138(13):1304-1316.
[29].Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.
[30].Asbeutah AAA,Asbeutah SA,Abu-Assi MA. A meta-analysis of cardiovascular outcomes in patients with hypercholesterolemia treated with inclisiran[J]. Am J Cardiol,2020,128:218-219.
[31].Zhang XL,Zhu QQ,Zhu L,et al. Safety and efficacy of anti-PCSK9 antibodies:a meta-analysis of 25 randomized,controlled trials[J]. BMC Med,2015,13:123.